News - Appointments

PhoreMost Ltd, a 2015 spin-out from Cambridge University with technology for identifying new drug targets, has appointed Lorenz Mayr to its board as a non-executive director.

Patrick Tricoli has become global head of business development at Nanobiotix SA following a corporate reorganisation which also saw Edwina Baskin-Bey become chief medical officer and Elsa Borghi head of drug discovery.

UK entrepreneur John Burt has been named chief executive of Medherant Ltd, a company with a clinical-stage transdermal patch for the treatment of pain.

Matthew Hill has joined UK-based Evonetix Ltd as head of mechanical engineering to help guide development of the company’s silicon chip technology for the synthesis of DNA. He was previously business manager at Cambridge Consultants which is an investor in Evonetix.

UK-based TrakCel Ltd has expanded its management team in the US with the appointment of Maryellen Papelian as senior director for customer delivery. TrakCel provides software for organising IT and other services for the cell and gene therapy industry.

Giorgio Calderari, chief operating officer and general manager of the Helsinn Group, has joined the board of directors of Helsinn Holding SA following the departure of Carlo Donati who stepped down after eight years of service.

Jens-Peter Marschner, a medical doctor and expert in drug development, has joined Zelluna Immunotherapy AS as chief medical officer to help advance the company’s lead T cell receptor product into the clinic.

Biotech entrepreneur Jonathan Montagu has joined the board of OMass Therapeutics Ltd as a non-executive director to help guide the company’s drug discovery activities. Founded in 2016, OMass uses structural mass spectrometry to discover new drug compounds.

John Haurum, formerly chief executive of F-star Biotechnology Ltd, has been appointed to the board of Storm Therapeutics Ltd as an independent non-executive director. Storm is focused on the discovery of small molecule therapies that modulate RNA epigenetics.

Adrian Rawcliffe has been promoted to the position of chief executive of Adaptimmune Therapeutics Plc, succeeding co-founder James Noble who will retire on 1 September. Mr Rawcliffe has been chief financial officer since 2015 when he joined Adaptimmune from GlaxoSmithKline Plc.